4Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines [J]. Leukemia, 2000,14 (5) : 841.
5Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronie acid [J]. J Pharmacol Exp Ther, 2002,302 ( 3 ) : 1055.
6Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadeha T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma [J]. Blood, 2000, 96(2) :384.
7Barille S, Akhoundi C, Collette M, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of pro MMP-2, and induction of MMP-1 by myeloma cells [J]. Blood, 1997,90(4) : 1649.
8Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials [J]. J Clin Oncol, 2001,19(2):558.
9Rosen L S, Gordon D, Kaminski M, et al, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase Ⅲ, double-bllnd, eomparativetrial [J]. Cancer J, 2001,7 (5) : 377.
10Rosen L S, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial [J]. Cancer, 2003,98 (8) :1735.
二级参考文献8
1Yeh HS,Berenson JR.Myeloma hone disease and treatment options.Eur J Cancer,2006,42:1554-1563.
2Hata H.Bone lesions and macrophage inflammatory protein-1 alpha(MIP-la)in human multiple myeloma.Leuk Lymphoma,2005,46:967-972.
3Terpos E,Szydlo R,Apperley JF,ct al.Soluble receptor activator of nuclear factor kappaB ligand osteoprotegerin ratio predicts survival in multiple myeloma:proposal for a novel prognostic index.Blood,2003,102:1064-1069.
4Alexandrakis MG,Passam FH,Sfiridaki A,et al.Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma:correlation with markers of disease activity.Am J Hematol,2003,72:229-233.
5Silvestris F,Lombardi L,De Malteo M,et al.Mye[oma bone disease:Pathogenetic mechanisms and clinical assessment.Leuk Res,2007,31:129-138.
6Lacy MQ,Dispenzieri A,Gertz MA,et al.Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.Mayo Clin Proc,2006,81:1047-1053.
7Heider U,Kaiser M,Muller C,et al.Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.Eur J Haematol,2006,77:233-238.
8Dewar AL,Farrugia AN,Condina MR.et al.Imatinib as a potential antiresorptive therapy for bone disease.Blood,2006,107:4334-4337.
8Corso A,Zappasodi P,Lazzarino M.Urinary proteins and renal dysfunction in patients with multiple myeloma[J].Biomed Pharmacother,2002,56(3):139-143.
9Prakash J,Mandal A K,Vohra R,et al.Renal disease is a prodrome of multiple myelo-ma:an analysis of 50 patients from eastern India[J].Renal Failure,2009,31(4):267-271.
10WislOff F,Kvam A K,Hjorth M,et al.Serum calcium is an independent predictor of quality of life in multiple myeloma[J].Eur J Haematol,2007,78(1):29-34.
